Disease Site: Gynecologic Cancers
4 protocol(s) meet the specified criteria
- 4010-01-001A Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors.
- EAY131Molecular Analysis for Therapy Choice (MATCH)
- NRG-GY009A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolozumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
- RRX001-211-01A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Readministration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)